PRO Research
Osiris Therapeutics' Survival In Doubt After Losing 'Pass-Through' Status In 2015
Probio Invest • 14 Comments
Probio Invest • 14 Comments
Osiris Focuses On Biosurgery After Selling Prochymal, Stock Attractively Valued
Andy Batts • 10 Comments
Andy Batts • 10 Comments
-
-
-
-
-
-
-
-
-
-
SA News • Dec. 17, 2015
-
-
-
-
-
From other sites
-
at 4-traders.com (Nov 27, 2015)
-
at Zacks.com (Nov 20, 2015)
-
at Nasdaq.com (Oct 13, 2015)
-
at Zacks.com (Aug 6, 2015)
-
at Zacks.com (May 11, 2015)
-
at 4-traders.com (Mar 23, 2015)
-
at Zacks.com (Mar 9, 2015)
Visit Seeking Alpha's
Company Description
Osiris Therapeutics, Inc. engages in stem cell research and development of pharmaceutical products. Its regenerative medicine targets dermal burns, pressure ulcers, venous leg, diabetic foot ulcers, and tissue and bone repair. The company was founded by Peter A. Friedli and James S. Burns on...
More